

Pathways to Alzheimer's disease

<https://www.neurodegenerationresearch.eu/survey/pathways-to-alzheimer%c2%92s-disease/>

Principal Investigators

Henrik Zetterberg

Institution

Gothenborg University

Contact information of lead PI

Country

Sweden

Title of project or programme

Pathways to Alzheimer's disease

Source of funding information

The Swedish Brain Foundation

Total sum awarded (Euro)

€ 108,814

Start date of award

01/07/2015

Total duration of award in years

2.5

Keywords

Research Abstract

Using patient materials in conjunction with cell, zebrafish and hippocampal slice models, we will address four major hypotheses of fundamental importance to the AD research field:

(i) Many patients diagnosed with clinical AD do not have AD neuropathology.

(ii) Amyloid build-up in AD is caused by imbalance in the production and clearance of specific Abeta isoforms.

(iii) Abeta needs brain incubation over years to become toxic.

(iv) Gamma-Secretase dysfunction and/or microglial activation mediate Abeta toxicity.

The uniqueness of the project lies in the combination of well-characterised clinical materials

(including cerebrospinal fluid samples [CSF; the fluid that surrounds the brain and

communicates freely with the brain interstitial fluid] and brain specimens), state-of-the-art clinical

laboratory testing, groundbreaking approaches to biomarker discovery, and both novel and established animal and cell models. The proposed research is translational and involves clinical and pre-clinical units at the Sahlgrenska University Hospital and the Sahlgrenska Academy, as well as several national and international collaborators.

Further information available at:

Types:

Investments < €500k

Member States:

Sweden

Diseases:

N/A

Years:

2016

Database Categories:

N/A

Database Tags:

N/A